The post Bitcoin ‘is done’ if it crosses this level, according to expert appeared on BitcoinEthereumNews.com. Bitcoin (BTC) is approaching a make-or-break technicalThe post Bitcoin ‘is done’ if it crosses this level, according to expert appeared on BitcoinEthereumNews.com. Bitcoin (BTC) is approaching a make-or-break technical

Bitcoin ‘is done’ if it crosses this level, according to expert

Bitcoin (BTC) is approaching a make-or-break technical level that has historically defined the transition from bull markets to deep bear cycles, according to a trading expert.

This outlook comes after Bitcoin lost the $90,000 support amid the broader cryptocurrency market sell-off, partly triggered by waning interest in risk assets. To this end, Bitcoin has seen a notable exodus of institutional investors.

Now, a TradingShot analysis shared on TradingView on January 26 shows Bitcoin trading just below the one-month Bollinger Bands Basis in the mid-$80,000s, with the spot price near $87,000 as the monthly close approaches. The analysis warns that time is running out for a recovery, as failure to reclaim this level has historically carried major downside implications.

Bitcoin price analysis chart. Source: TradingView

The one-month Bollinger Bands Basis has served as a long-term regime divider for more than a decade. Over the past 12 years, every monthly close below this level has signaled the start of Phase 2 of a bear cycle. Bitcoin has now spent three straight months testing and trading below the basis, a setup that has never turned bullish without a decisive month-end reclaim.

Key Bitcoin price levels to watch 

A confirmed monthly close below the $85,000–$88,000 zone would likely expose deeper weekly support, with the first major downside target at the one-week MA200 near $50,000, a level reached in every bear cycle and which marked the January 2015 and December 2018 bottoms.

TradingShot also pointed to the one-week MA350 in the mid- to high-$40,000s as a more complete bear-cycle target. This moving average marked the November 2022 bottom and, in the prior cycle, was not tested until the bearish phase was fully exhausted.

A potential bottom around $50,000 aligns with the 0.382–0.5 Fibonacci retracement of the full bull-market advance, a zone that has contained all prior cycle lows. The convergence of the weekly MA200, MA350, and Fibonacci support reinforces this area as a likely macro floor if bearish conditions persist.

The analysis notes that a new bull cycle has only been confirmed after Bitcoin reclaimed and held above the one-week MA200, as seen in March 2023. Until a similar reclaim occurs, a monthly close below the one-month Bollinger Bands Basis would statistically signal bear-market continuation rather than a temporary correction.

Bitcoin price analysis 

By press time, Bitcoin was trading at $87,762, down more than 3% on the weekly timeframe. Year-to-date, the leading cryptocurrency is down less than 1%.

Bitcoin seven-day price analysis. Source: Finbold

From a technical perspective, Bitcoin’s price sits below both key moving averages, the 50-day simple moving average at $90,192 and the 200-day simple moving average at $104,666, a classic bearish signal indicating that both the short- and long-term trends remain under downward pressure. 

Meanwhile, the 14-day Relative Strength Index stands at 41.64, which is neutral but skewed toward weakness, suggesting limited bullish momentum at present.

Featured image via Shutterstock

Source: https://finbold.com/bitcoin-is-done-if-it-crosses-this-level-according-to-expert/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26